Human T lymphotropic virus type 1 (HTLV-I) is the causative agent of adult T cell leukemia/lymphoma. Recently, Kawa et al 1 reported complete eradication of HTLV-I by allogeneic bone marrow transplantation (BMT) from an HLA-identical, HTLV-I negative sibling donor. This result differs somewhat from our experience.
A 22-year-old man received an allogeneic bone marrow transplant for acute myelocytic leukemia. He was a carrier of HTLV-I, but the HLA-identical sibling donor was negative for the virus. The preparative regimen consisted of busulfan (total dose 16 mg/kg) and cyclophosphamide (total dose 120 mg/kg). Engraftment was prompt and the clinical course after BMT was uneventful except for grade I acute graft-versus-host disease. The serial antibody titers for HTLV-I before and after BMT are shown in Table 1 . The antibody to HTLV-I is still positive 37 months after BMT. Although we did not perform polymerase chain reaction (PCR) for HTLV-I DNA, it is logical to presume that the virus is still present in the recipient, because eradication of the virus was accompanied by the disappearance of the antibody in the patient reported by Kawa et al.
There have been few reports describing the course of HTLV-I infection after BMT. [1] [2] [3] In the cases reported by Kawa et al and Borg et al, respectively, HTLV-I DNA had become negative after 6 and 24 months after BMT by PCR assay using cells from bone marrow or peripheral blood. 1, 2 However, the serum antibody for HTLV-I remained positive 23 and 37 months after BMT in the case reported by Borg et al and in our case, respectively.
2 (Borg et al suggested that the discrepancy between the findings on PCR and antibody titer might result from infection in an extramedullary site or infection at a level below the sensitivity of the PCR). In addition, Ljungman et al 3 reported an infection with HTLV-I in donor lymphocytes after BMT for an Table 1 Serial changes in the antibody titer for HTLV-I
Months after BMT −1 1 5 7 10 38 Antibody titer ×16 ×16 ×32 ×32 ×16 ×64
HTLV-I positive adult T cell leukemia patient. It is known that lethally irradiated genome-carrying lymphocytes are still capable of releasing HTLV-I, which might cause cellto-cell transmission of the virus. 4 Considering these case reports and the in vitro data, eradication of HTLV-I by allogeneic BMT may not be a common phenomenon.
The myelo-lymphoid-ablative preparative regimen of our patient was the same as that of the patient reported by Kawa et al. The major difference between the two patients was a high antibody titer (×128-×256) early after BMT in their patient. The high antibody titer, for which the reason is not clear, might prevent infection of donor cells with HTLV-I. Allogeneic bone marrow transplantation from an HTLV-I negative donor followed by passive immunization with HTLV-I immune globulin may eradicate the virus. 4 However, such treatment is not appropriate for HTLV-I carriers, because transplant-related mortality probably exceeds the lifetime risk of developing a severe disease in this population. 
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